Status:
TERMINATED
SHARED Study (Saguenay Hospitals Anaphylaxis Rule for Early Discharge)
Lead Sponsor:
Université de Sherbrooke
Conditions:
Anaphylaxis
Biphasic Anaphylactic Reaction
Eligibility:
All Genders
Brief Summary
Anaphylaxis is a potentially fatal condition with a prevalence between 0.05 and 2% in the general population. This is therefore a frequent reason for emergency visits. Its diagnosis is mainly based on...
Detailed Description
This study is part of an ongoing projet to create, derive and validate a clinical decision rule with regards to the stratification of the biphasic reaction risk following an anaphylaxis event that has...
Eligibility Criteria
Inclusion
- Patients of all ages with anaphylaxis (meeting the NIAID/FAAN criteria)
- Patients of all ages considered to be inevitably evolving torwards overt anaphylaxis by the threading physician
Exclusion
- Adverse reaction to a medication (eg ACEI)
- Hereditary angioedema
- Known immune mediated Angioedema
- Anaphylactoid reaction
Key Trial Info
Start Date :
December 3 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 7 2023
Estimated Enrollment :
191 Patients enrolled
Trial Details
Trial ID
NCT04755881
Start Date
December 3 2019
End Date
March 7 2023
Last Update
March 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'urgence CIUSSS du Saguenay - Lac-St-Jean
Saguenay, Quebec, Canada, G7H 5H6